Our findings agree with those of Kiortsis, et al. [20] who reported significant decrease in HOMA-IR and increase in QUICKI among patients with RA and ankylosing spondylitis in the highest tertile of insulin resistance, suggesting that this subset of patients may benefit most from anti-TNF therapy. This evidence concerns the gene TNF and ankylosing spondylitis.